Which sedative-hypnotic is the only one approved for long-term use to treat chronic insomnia?

Which sedative-hypnotic is the only one approved for long-term use to treat chronic insomnia?

• A. Phenobarbital
• B. Zolpidem
• C. Ramelteon
• D. Diazepam

Answer: (C)

Ramelteon is the only sedative-hypnotic approved for long-term use to treat chronic insomnia due to its unique mechanism of action and safety profile. Unlike other sedative-hypnotics, which can lead to dependence and tolerance issues with prolonged use, ramelteon is a melatonin receptor agonist that mimics the action of melatonin, a hormone that regulates sleep-wake cycles. This action allows it to promote sleep without the same risks associated with dependence that are prevalent with other sedative-hypnotics. Other options, such as phenobarbital, zolpidem, and diazepam, are associated with concerns of tolerance, dependence, and withdrawal symptoms, making them less ideal for chronic use. For instance, phenobarbital is a barbiturate that can lead to significant addiction issues and is usually not recommended for long-term insomnia management. Zolpidem, a non-benzodiazepine, is effective for short-term use but carries risks of dependence and is generally not recommended for long-term therapy. Diazepam, a benzodiazepine, similarly poses risks of tolerance and dependence related to its sedative effects. Therefore, ramelteon stands out as a safer long-term option for patients

Ramelteon is the only sedative-hypnotic approved for long-term use to treat chronic insomnia due to its unique mechanism of action and safety profile. Unlike other sedative-hypnotics, which can lead to dependence and tolerance issues with prolonged use, ramelteon is a melatonin receptor agonist that mimics the action of melatonin, a hormone that regulates sleep-wake cycles. This action allows it to promote sleep without the same risks associated with dependence that are prevalent with other sedative-hypnotics.

Other options, such as phenobarbital, zolpidem, and diazepam, are associated with concerns of tolerance, dependence, and withdrawal symptoms, making them less ideal for chronic use. For instance, phenobarbital is a barbiturate that can lead to significant addiction issues and is usually not recommended for long-term insomnia management. Zolpidem, a non-benzodiazepine, is effective for short-term use but carries risks of dependence and is generally not recommended for long-term therapy. Diazepam, a benzodiazepine, similarly poses risks of tolerance and dependence related to its sedative effects. Therefore, ramelteon stands out as a safer long-term option for patients